- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
ADC Sequencing
August 22, 2024
Video
Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.
Case Study Highlights an Approach to Adjuvant Treatment in RCC
August 22, 2024
Article
Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.
Dr Ravi on the Investigation of RCB Following ARPI Treatment in High-Risk Prostate Cancer
August 21, 2024
Video
Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.
Dr McGregor on the Future Implications of Ongoing Research in RCC
August 21, 2024
Video
Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.
Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer
August 20, 2024
Video
Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.
Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma
August 20, 2024
Video
Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.
Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC
August 19, 2024
Video
Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.
Retrospective Study Exemplifies the Environmental and Health Impacts of Decentralizing Cancer Care
August 18, 2024
Article
Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.
Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials
August 16, 2024
Article
Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.
Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC
August 16, 2024
Article
Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.
Management of Emetogenicity of Antibody-Drug Conjugates
August 15, 2024
Video
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
Managing Hematologic AEs Associated with ADC Treatments
August 15, 2024
Video
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
August 15, 2024
Video
Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.
Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
August 15, 2024
Video
A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.
Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care
August 15, 2024
Video
Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.
Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer
August 14, 2024
Video
Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.
Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer
August 13, 2024
Video
Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.
Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?
August 11, 2024
Article
Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.
Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment
August 09, 2024
Video
Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.
Dr Machaalani on the Interaction Between c-Met and AXL in RCC
August 09, 2024
Video
Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.